AbbVie on Friday said it will post a $3.5 billion impairment charge related to last year's $8.7 billion bet on Cerevel Therapeutics following the failure of the deal's key drug candidate.

RingCentral (RNG) shares have gained nearly 19% over the past six months, driven by expanding AI initiatives, strong demand ...

Starting later this year, Ouro intends to start a phase 1 clinical trial of its own, eyeing the development of the drug for ...

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...